19:39 , Oct 10, 2018 |  BC Extra  |  Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
18:38 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Y-mAbs aims for $92M IPO

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million on Aug. 24 in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG. Y-mAbs hopes to submit...
22:14 , Aug 24, 2018 |  BC Extra  |  Financial News

Y-mAbs aiming for $92M IPO

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG. Y-mAbs hopes to submit BLAs next year...
20:35 , Jun 6, 2018 |  BC Innovations  |  Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of...
21:59 , Jan 2, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Bioinformatic screens; cell-free assays A low-cost computational method for quantifying tumor cfDNA could identify cancer patients eligible for high-cost, whole-exome sequencing-based personalized medicine. The method quantifies tumor cfDNA in blood using the low-cost method...
21:30 , Nov 16, 2017 |  BC Innovations  |  Tools & Techniques

Internal logic

Instead of designing T cells to fight cancer, an MIT group is using synthetic biology to directly manipulate the tumor cells and make them more immunogenic. The big advantage, says the team, is that the...
01:59 , Dec 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

BNC210: Phase II data

Top-line data from the double-blind, placebo- and lorazepam-controlled, 4-way crossover, U.K. Phase II BNC210.006 trial in 24 patients with untreated GAD showed that a single oral dose of 300 mg BNC210 met the co-primary endpoints...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

BNC210: Completed Phase II enrollment

Bionomics completed enrollment of 24 patients in a double-blind, 4-way crossover, U.K. Phase II trial comparing 300 and 2,000 mg oral BNC210 vs. placebo or lorazepam. Bionomics Ltd. (ASX:BNO; OTCQX:BNOEF), Thebarton, Australia   Product: BNC210...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

BNC210: Phase Ib data

A double-blind, placebo-controlled, French Phase Ib trial in 54 healthy volunteers showed that once-daily doses of 300-2,000 mg oral BNC210 for 8 days were well tolerated. The maximum tolerated dose (MTD) was not reached and...